SOMERSET, N.J., Sept. 15 /PRNewswire-FirstCall/ -- Ventiv Pharma Services, Division of Ventiv Health, Inc. today announced the appointment of Jack Rubin to the newly created position of Chief Compliance Officer, Ventiv Pharma Services. In this role, Mr. Rubin will have responsibility for compliance guidelines and ensuring compliance across the Ventiv Pharma Services portfolio of offerings to the pharmaceutical and biotech industries. In addition to compliance issues, Mr. Rubin will also work closely with Ventiv’s Business Development group to identify new business opportunities within the compliance arena.
Prior to joining Ventiv, Mr. Rubin served as President/CEO of integrated Pharma Technologies from May 2001 through May 2004, during which time iPT experienced unprecedented growth in both sales and earnings. Mr. Rubin joined iPT from Roche Laboratories, Inc. (“Roche Labs”) where he headed the Sample Accountability and Patient’s Assistance Departments.
Terry Herring, COO and President, Ventiv Pharma Services(TM) commented, “We are delighted that Jack Rubin has joined our team at Ventiv, especially at a time when compliance and compliance-related issues are at the forefront of the planning process among pharmaceutical companies. Jack’s role as Compliance Officer, along with our recent acquisition of The Franklin Group, will allow our portfolio of companies, as well as our clients, to obtain the most comprehensive information in this area from experts in sample accountability, PDMA, OIG and patient/assistance programs.”
“I’m very excited at the opportunity this role provides me at Ventiv,” said Jack I. Rubin. “I look forward to working with all of the specialty areas within Ventiv and to collaborating with our partner clients in the pharma and biotech industries on issues that are top-of-mind in this current compliance-sensitive marketplace.”
At Roche Labs, Mr. Rubin built his reputation as an industry leader in the development and implementation of programs to drive sales force automation and ensure regulatory compliance. While at Roche, Mr. Rubin managed the regulatory compliance issues for a sales force of 3,000 pharmaceutical sales representatives and managers that had annual sales of $2.7 billion.
Mr. Rubin is a well-known expert on issues surrounding sample accountability and regulatory compliance within the pharmaceutical industry. He has published extensively in trade journals and lectured in the U.S. on issues surrounding the Prescription Drug Marketing Act and Patient Assistance Programs. He served on the Board of the PDMA Sharing Conference and as a Co-Chair of the 2000 PDMA Sharing Conference. The PDMA Sharing Conference is the industry association that advises its member pharmaceutical companies with respect to the activities of the approximately 80,000 pharmaceutical sales representatives in the U.S.
Mr. Rubin received his Bachelor of Science in Biology from Brooklyn College. Thereafter, he was awarded a Doctor of Chiropractic Degree from Columbia University.
About Ventiv Health
Ventiv Health, Inc. is a leading provider of sales, marketing, and compliance solutions to the world’s largest pharmaceutical companies as well as to emerging and specialty pharmaceutical and biotech organizations. Ventiv has established its leadership position within the industry based on a long history of building and managing sales teams and providing consultative planning and analytics services across multiple therapeutic areas.
The Ventiv delivery model is flexible and client focused, enabling Ventiv to rapidly respond to changing client needs and market conditions across the full spectrum of sales and marketing support, with both integrated and independent programs. These include: Sales and Marketing Teams (Ventiv Sales and Marketing Teams(TM)), Planning and Analytics (Health Products Research(R)), Recruitment (Ventiv Recruitment Services(TM)), Professional Development and Training (Ventiv Professional Development Group(TM)), Marketing Support (PROMOTECH), Data Solutions (Total Data Solutions(TM)), Clinical Support (The Therapeutics Institute(TM)), and Sample Accountability/Patient Assistance Programs (The Franklin Group). Ventiv is a multi-discipline company with a singular focus on providing excellence in customized solutions to meet clients’ sales and marketing objectives.
Ventiv’s approximately 2,600 employees support over forty client organizations, including a number of the world’s leading pharmaceutical companies as well as emerging and specialty pharmaceutical and biotech organizations. For more information on Ventiv Health, visit http://www.ventiv.com/.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health’s performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
Ventiv Health, Inc.
CONTACT: Investors/Corporate - John Emery, CFO of Ventiv Health, Inc.,+1-732-537-4804, investor@ventiv.com; or Media - Felicia Vonella of LazarPartners, +1-212-867-1762, fvonella@lazarpartners.com, for Ventiv Health,Inc.
Web site: http://www.ventiv.com/
